Is carvedilol dialyzable and does it require dose adjustment in patients with end‑stage renal disease on intermittent hemodialysis?

Carvedilol is Non-Dialyzable

Carvedilol is not removed by hemodialysis and does not require dose adjustment or supplementation after dialysis sessions in patients with end-stage renal disease. 1, 2

Dialyzability Classification

• The EXTRIP workgroup definitively classified carvedilol as non-dialyzable, with approximately 0% of the ingested dose recovered in dialysate during hemodialysis 1, 3
• The FDA label confirms that carvedilol "does not appear to be cleared significantly by hemodialysis" due to its high degree of plasma protein binding (>98%) 2
• This non-dialyzability stems from carvedilol's physicochemical properties: high lipophilicity, extensive protein binding, and large volume of distribution (115 L) 2, 4

Pharmacokinetic Studies in Dialysis Patients

• Multiple pharmacokinetic studies demonstrate no difference in carvedilol levels between dialysis and non-dialysis days, confirming lack of dialytic removal 4, 5
• A randomized crossover trial (2018) measured dialytic clearance of carvedilol at only 0.2 ml/min using recovery clearance method and 24 ml/min using arterial-venous difference method—both negligible compared to atenolol (72-167 ml/min) and metoprolol (87-114 ml/min) 6
• No accumulation of carvedilol or its active metabolite M2 occurs with repeated dosing in hemodialysis patients 4, 5

Dosing Recommendations

• No dose adjustment is required for carvedilol in hemodialysis patients 4, 5
• No supplemental dosing is needed after dialysis sessions, unlike dialyzable beta-blockers (atenolol, metoprolol, bisoprolol) which require post-dialysis administration 7, 6, 8
• Carvedilol can be administered on both dialysis and non-dialysis days without timing considerations related to the dialysis session 4, 5

Clinical Implications and Caveats

Advantages of Non-Dialyzability:

• Maintains consistent therapeutic effect throughout and after dialysis 3
• May improve medication adherence due to simpler dosing schedule 3
• K/DOQI guidelines recommend carvedilol as the preferred beta-blocker for dialysis patients with severe dilated cardiomyopathy, based on demonstrated reduction in cardiovascular deaths and total mortality 9, 7

Critical Warning - Intradialytic Hypotension:

• For patients with frequent intradialytic hypotension, avoid carvedilol and other non-dialyzable beta-blockers 3, 7
• The persistent drug effect during dialysis increases risk of hypotension when combined with ultrafiltration 9, 3
• Some retrospective data suggest higher mortality rates with carvedilol versus dialyzable metoprolol, possibly due to intradialytic hypotension risk 3
• One study reported 30% dropout rate due to hypotension with ACE inhibitors in dialysis patients; similar caution applies to carvedilol 9

When to Use Carvedilol:

• Preferred in dialysis patients with stable intradialytic blood pressure and dilated cardiomyopathy 9, 7
• Effective for hypertension control (reduces BP from ~170/98 to ~145/85 mmHg) 4, 5
• Reduces ventricular arrhythmias in dialysis patients with hypertension or coronary disease 10

Contrast with Dialyzable Beta-Blockers:

• Atenolol (dialyzable) should be administered after dialysis to avoid removal and loss of therapeutic effect 7, 8
• Metoprolol and bisoprolol are significantly dialyzable and require supplementation 6, 8